DISTINCT DESIGN OF TENDYNE™ TMVI ENABLES DEVICE CONTROL
A breakthrough TECHNOLOGY DESIGNED TO ELIMINATE MITRAL REGURGITATION
- Designed with the unique challenges of the mitral anatomy in mind
- Beating heart procedure—no requirement for cardiopulmonary bypass or rapid pacing
Dual-frame design with ability to customize fit to individual patient anatomies
Self-expanding. tri-leaflet, bioprosthetic valve
Contoured design supports a secure seal over native anatomy
Tether and pad
The distinct design enables safe and effective treatment for a broad range of patients.
- Contoured, dual-frame design conforms to mitral annulus for sealing and securement
- Low risk for paravalvular leak1
- Two valve profiles available to reduce risk of left ventricular outflow tract (LVOT) obstruction
- A wide range of annular dimensions due to array of valve sizes
IMPLANT WITH CONFIDENCE
- Controlled and predictable procedure
- Supported procedural planning
- Fully retrievable intraprocedurally and repositionable for optimal valve placement
MAT-2000613 v4.0 | Item approved for Global OUS use only.
- Muller, D. Two-Year Outcomes of Tendyne Transcatheter Mitral Valve Implantation to Treat Symptomatic, Severe Mitral Regurgitation. David Muller. Presented at: PCR E-Course, June, 2020.
- Abbott Medical Internal Document. Expanded Clinical Study of Tendyne Mitral Valve System “CE Study” Clinical Study Report. Study Document No: CL1010682.